Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 12;86(1):98-105.
doi: 10.1055/s-0044-1779050. eCollection 2025 Feb.

Prediction of Survival in the Elderly Patients with Glioblastoma using Cumulative Inflammatory Markers Score

Affiliations

Prediction of Survival in the Elderly Patients with Glioblastoma using Cumulative Inflammatory Markers Score

Kun Song et al. J Neurol Surg B Skull Base. .

Abstract

Objectives This retrospective study aimed to explore the prognostic effect of cumulative score based on neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and fibrinogen in older adults diagnosed with glioblastoma (GBM). Design Retrospective study. Setting Huashan Hospital. Participants Patients aged over 60 years and diagnosed with GBM between 2010 and 2017. Main Outcome Measures Results of preoperative routine biochemistry and coagulation blood examinations were reviewed from medical records. Overall survival (OS) was considered a period from first resection surgery until death. Progression-free survival (PFS) was considered a period from initial operation until the date of tumor progression demonstrated in brain magnetic resonance imaging or death from any cause. If no event occurred, the last follow-up appointment was the end of the observation for OS or PFS. The Kaplan-Meier method was used to evaluate survival curves, and prognostic factors were analyzed by the Cox proportional hazards model. Results A total of 289 patients were included. Patients with higher levels of fibrinogen, NLR, and PLR had significantly shorter median OS ( p = 0.001, p = 0.016, and p = 0.002, respectively) and PFS ( p = 0.004, p = 0.022, and p = 0.009, respectively) compared with those with lower levels. Multivariate analyses showed a significant association between higher F-NLR-PLR score and reduced OS (adjusted hazard ratios [aHRs]: 1.356, 95% confidence interval [CI] 1.009-1.822 for scores 1-2 compared with 0; 5.974, 95% CI 2.811-12.698 for score 3 compared with 0). Similarly, a significant association between higher F-NLR-PLR score and reduced PFS was observed (aHR: 1.428, 95% CI 1.066-1.912 for scores 1-2 compared with 0; aHR: 2.860, 95% CI 1.315-6.223 for score 3 compared with 0). Conclusion Higher F-NLR-PLR score is associated with reduced OS and PFS in older adults with GBM, which helps identify patients at high risk and guide the individualized treatment in clinical practice.

Keywords: fibrinogen; glioblastoma; neutrophil–lymphocyte ratio; platelet–lymphocyte ratio.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest None declared.

Figures

Fig. 1
Fig. 1
Kaplan–Meier estimates of OS in older adults with GBM stratified by F-NLR-PLR score (A, C) . Kaplan–Meier estimates of PFS in older adults with GBM stratified by F-NLR-PLR score (B, D) . High plasma fibrinogen level (≥4 g/L) was defined as 1, low plasma fibrinogen level (≥4 g/L) was calculated as 0. Similarly, for NLR and PLR, above or equal to the cutoff value (4 and 180, respectively) were defined as 1, while lower than the cutoff value was calculated as 0. The F-NLR-PLR score was the sum of fibrinogen, NLR, and PLR scores. GBM, glioblastoma; F, fibrinogen; NLR, neutrophil-to-lymphocyte ratio; OS, overall survival; PFS, progression-free survival; PLR, platelet-to-lymphocyte ratio.

References

    1. Ostrom Q T, Gittleman H, Farah Pet al.CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010 Neuro Oncol 201315(Suppl 2)ii1–ii56. - PMC - PubMed
    1. Darefsky A S, King J T, Jr, Dubrow R. Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries. Cancer. 2012;118(08):2163–2172. - PMC - PubMed
    1. Guedes de Castro D, Matiello J, Roa W et al.Survival outcomes with short-course radiation therapy in elderly patients with glioblastoma: data from a randomized Phase 3 trial. Int J Radiat Oncol Biol Phys. 2017;98(04):931–938. - PubMed
    1. Association of French-Speaking Neuro-Oncologists . Keime-Guibert F, Chinot O, Taillandier L et al.Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356(15):1527–1535. - PubMed
    1. Nordic Clinical Brain Tumour Study Group (NCBTSG) . Malmström A, Grønberg B H, Marosi C et al.Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(09):916–926. - PubMed